Diabetes company shares hit a low

According to reports from the international diabetes arena, shares in San Diego based Amylin Pharmaceuticals Inc. dropped to a two-year low this week. The slide in shares in the diabetes company is a further representation of declines in the biotechnology sector.
However, the horizon is not bleak for Amylin. Their experimental diabetes drug exenatide LAR is likely to dominate the drug market, and could fuel the growth of the company . The drug is a long-acting release diabetes treatment agent, and is taken by diabetics once a week.
Amylin are in a production partnership for the drug with Alkermes Inc. and Eli Lilly, the drug giant. The drug could potentially replace Byetta, the current Amylin diabetes drug. Early-stage clinical trials indicate that exenatide is more effective at controlling blood glucose .
A number of exciting new diabetes drug products are likely to hit the market in the next couple of years.